AI MARKET SCANNING

Akebia Therapeutics, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Drug Manufacturers – Specialty & Generic
AVG HISTORICAL GAP -6.37%
MAX GAP RECORD -30.08%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $AKBA
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE)
-30.08%
May 07, 2026 Earnings Release 2026-05-07 (BEFORE OPEN)
-22.97%
Feb 26, 2026 Earnings Release 2026-02-26 (BEFORE OPEN)
+21.07%
Nov 10, 2025 Earnings Release 2025-11-10 (BEFORE OPEN)
-15.20%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
-15.32%
May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN)
+1.72%
Mar 13, 2025 Earnings Release 2025-03-13 (BEFORE OPEN)
-6.74%
Nov 07, 2024 Earnings Release 2024-11-07 (BEFORE OPEN)
-13.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 12.2%
Bullish Gaps (4)
Bearish Gaps (11)
Neutral / Flat (0)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $AKBA

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients;…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗